Clinical Trials › NCT04926818
Active, Not RecruitingPhase 3
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 129
Target enrollment
6
U.S. states
Oct 2021
Start date
Mar 2031
Expected completion
Interventions / Treatments
FingolimodOfatumumabSiponimodFingolimod placeboSiponimod placeboOfatumumab placebo
Conditions studied
Multiple Sclerosis (MS)
Where this trial is running (6 sites)
Arkansas1 site
Little Rock
California1 site
Los Angeles
District of Columbia1 site
Washington D.C.
Florida1 site
Tampa
Pennsylvania1 site
Philadelphia
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (3)
Children's Hospital of Philadelphia Pediatric MS Clinic
Philadelphia, PA
Philadelphia, PA
Children's Hospital Los Angeles Neuroimmunology Program
Los Angeles, CA
Los Angeles, CA
MS centers in Arkansas
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Arkansas centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
